Therapeutic agents such as GLP-1 RAs exemplify emerging possibilities in personalized medicine, where comprehensive understanding of pathophysiology guides innovative, patient-tailored therapeutic strategies aiming to improve prognosis and quality of life in HF patients. This evidence concerns the gene GLP1R and hydrops fetalis.